Cargando…
Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial
Higher selenium status has been associated with lower bone turnover markers (BTM) in epidemiological studies. However, the long‐term impact of selenium supplementation on BTMs has not been studied. We investigated the effects of selenium supplementation on BTMs including osteocalcin (OC), procollage...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087503/ https://www.ncbi.nlm.nih.gov/pubmed/36093566 http://dx.doi.org/10.1002/jbmr.4703 |
_version_ | 1785022362851213312 |
---|---|
author | Perri, Giorgia Hill, Tom R Mathers, John C Walsh, Jennifer S Gossiel, Fatma Winther, Kristian Frölich, Jacob Folkestad, Lars Cold, Søren Eastell, Richard |
author_facet | Perri, Giorgia Hill, Tom R Mathers, John C Walsh, Jennifer S Gossiel, Fatma Winther, Kristian Frölich, Jacob Folkestad, Lars Cold, Søren Eastell, Richard |
author_sort | Perri, Giorgia |
collection | PubMed |
description | Higher selenium status has been associated with lower bone turnover markers (BTM) in epidemiological studies. However, the long‐term impact of selenium supplementation on BTMs has not been studied. We investigated the effects of selenium supplementation on BTMs including osteocalcin (OC), procollagen type I N‐terminal propeptide (PINP), collagen type I cross‐linked C‐telopeptide (CTX), and bone alkaline phosphatase (BALP) in the short (6 months) and long term (5 years). A total of 481 Danish men and women (60–74 years) were randomized to receive placebo‐yeast versus 100, 200, or 300 μg selenium as selenium‐enriched yeast daily for 5 years. Plasma selenium concentration was measured using inductively coupled plasma mass spectrometry, and BTMs were measured in nonfasted samples at baseline, 6 months, and 5 years. Data were analyzed by ANCOVA to investigate the shape of the dose‐response relationships. Covariates included age, body mass index, baseline selenium status, baseline BTM, smoking, alcohol, supplement use, and medication. Plasma selenium concentration (mean 86.5 μg/d at baseline) increased significantly with increasing selenium supplementation to 152.6, 209.1, and 253.7 μg/L after 6 months and remained elevated at 5 years (158.4, 222.4, and 275.9 μg/L for 100, 200, and 300 μg supplemental selenium/d, respectively (p < 0.001)). There was no change in plasma selenium concentration in the placebo‐treated group. There was no significant effect of selenium supplementation on OC (6 months p = 0.37; 5 years p = 0.63), PINP (6 months p = 0.37; 5 years p = 0.79), CTX (6 months p = 0.91; 5 years p = 0.58) or BALP (6 months p = 0.17; 5 years p = 0.53). The relatively replete baseline selenium status in the study participants may explain this lack of effect. Testing in more deficient populations may provide further insights into the impact of selenium supplementation on bone health. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). |
format | Online Article Text |
id | pubmed-10087503 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100875032023-04-12 Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial Perri, Giorgia Hill, Tom R Mathers, John C Walsh, Jennifer S Gossiel, Fatma Winther, Kristian Frölich, Jacob Folkestad, Lars Cold, Søren Eastell, Richard J Bone Miner Res Clinical Trial Higher selenium status has been associated with lower bone turnover markers (BTM) in epidemiological studies. However, the long‐term impact of selenium supplementation on BTMs has not been studied. We investigated the effects of selenium supplementation on BTMs including osteocalcin (OC), procollagen type I N‐terminal propeptide (PINP), collagen type I cross‐linked C‐telopeptide (CTX), and bone alkaline phosphatase (BALP) in the short (6 months) and long term (5 years). A total of 481 Danish men and women (60–74 years) were randomized to receive placebo‐yeast versus 100, 200, or 300 μg selenium as selenium‐enriched yeast daily for 5 years. Plasma selenium concentration was measured using inductively coupled plasma mass spectrometry, and BTMs were measured in nonfasted samples at baseline, 6 months, and 5 years. Data were analyzed by ANCOVA to investigate the shape of the dose‐response relationships. Covariates included age, body mass index, baseline selenium status, baseline BTM, smoking, alcohol, supplement use, and medication. Plasma selenium concentration (mean 86.5 μg/d at baseline) increased significantly with increasing selenium supplementation to 152.6, 209.1, and 253.7 μg/L after 6 months and remained elevated at 5 years (158.4, 222.4, and 275.9 μg/L for 100, 200, and 300 μg supplemental selenium/d, respectively (p < 0.001)). There was no change in plasma selenium concentration in the placebo‐treated group. There was no significant effect of selenium supplementation on OC (6 months p = 0.37; 5 years p = 0.63), PINP (6 months p = 0.37; 5 years p = 0.79), CTX (6 months p = 0.91; 5 years p = 0.58) or BALP (6 months p = 0.17; 5 years p = 0.53). The relatively replete baseline selenium status in the study participants may explain this lack of effect. Testing in more deficient populations may provide further insights into the impact of selenium supplementation on bone health. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). John Wiley & Sons, Inc. 2022-09-29 2022-11 /pmc/articles/PMC10087503/ /pubmed/36093566 http://dx.doi.org/10.1002/jbmr.4703 Text en © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Trial Perri, Giorgia Hill, Tom R Mathers, John C Walsh, Jennifer S Gossiel, Fatma Winther, Kristian Frölich, Jacob Folkestad, Lars Cold, Søren Eastell, Richard Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial |
title | Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial |
title_full | Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial |
title_fullStr | Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial |
title_full_unstemmed | Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial |
title_short | Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial |
title_sort | long‐term selenium‐yeast supplementation does not affect bone turnover markers: a randomized placebo‐controlled trial |
topic | Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087503/ https://www.ncbi.nlm.nih.gov/pubmed/36093566 http://dx.doi.org/10.1002/jbmr.4703 |
work_keys_str_mv | AT perrigiorgia longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial AT hilltomr longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial AT mathersjohnc longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial AT walshjennifers longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial AT gossielfatma longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial AT wintherkristian longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial AT frolichjacob longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial AT folkestadlars longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial AT coldsøren longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial AT eastellrichard longtermseleniumyeastsupplementationdoesnotaffectboneturnovermarkersarandomizedplacebocontrolledtrial |